Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024
United States Steel Revenue
Oncternal Therapeutics had revenue of $494.00K in the quarter ending September 30, 2024, with 175.98% growth. This brings the company's revenue in the last twelve months to $2.16M, up 227.92% year-over-year. In the year 2023, Oncternal Therapeutics had annual revenue of $785.00K, down -47.32%.
Revenue (ttm)
$2.16M
Revenue Growth
+227.92%
P/S Ratio
0.72
Revenue / Employee
$72,033
Employees
30
Market Cap
1.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 785.00K | -705.00K | -47.32% |
Dec 31, 2022 | 1.49M | -2.83M | -65.47% |
Dec 31, 2021 | 4.32M | 940.00K | 27.85% |
Dec 31, 2020 | 3.38M | 950.00K | 39.18% |
Dec 31, 2019 | 2.43M | -96.00K | -3.81% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionONCT News
- 4 weeks ago - Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations - GlobeNewsWire
- 5 months ago - Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics to Present in JonesTrading Healthcare Summit - GlobeNewsWire
- 1 year ago - Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 1 year ago - Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript - Seeking Alpha